Tissue engineering of skin and regenerative medici
Post# of 30067
(Total Views: 544)
Posted On: 07/06/2018 5:08:06 PM
Tissue engineering of skin and regenerative medicine for wound care - 2018
Steven T. Boyce and Andrea L. Lalley
Conclusions
Future prospects for biologic skin substitutes are extensive
and diverse. Advances in use and regulation of stem
cells in the skin are highly likely to lead to autologous
skin substitutes with greater homology to uninjured skin
by providing restoration of skin pigmentation, epidermal
appendages (hair, sebaceous and sweat glands), a vascular
plexus, and subcutaneous tissues. Genetic modification
of autologous cells opens tremendous opportunities
for regulation of wound closure, reductions in scar formation,
and correction of congenital diseases. As these
advances in biologic skin substitutes translate into
clinical care, it can be predicted with confidence that reductions
in morbidity from acquired and congenital skin
diseases will also be realized.
Funding
Funding of the authors’ studies has been provided by the National Institutes
of Health (grant no. 1R21AR064341-01A1), the US Department of Defense
(contract no. W81XWH-13-2-0052), and the Shriners Hospitals for Children
(grant nos. 85200 and 84050).
https://burnstrauma.biomedcentral.com/track/p...017-0103-y
Steven T. Boyce and Andrea L. Lalley
Conclusions
Future prospects for biologic skin substitutes are extensive
and diverse. Advances in use and regulation of stem
cells in the skin are highly likely to lead to autologous
skin substitutes with greater homology to uninjured skin
by providing restoration of skin pigmentation, epidermal
appendages (hair, sebaceous and sweat glands), a vascular
plexus, and subcutaneous tissues. Genetic modification
of autologous cells opens tremendous opportunities
for regulation of wound closure, reductions in scar formation,
and correction of congenital diseases. As these
advances in biologic skin substitutes translate into
clinical care, it can be predicted with confidence that reductions
in morbidity from acquired and congenital skin
diseases will also be realized.
Funding
Funding of the authors’ studies has been provided by the National Institutes
of Health (grant no. 1R21AR064341-01A1), the US Department of Defense
(contract no. W81XWH-13-2-0052), and the Shriners Hospitals for Children
(grant nos. 85200 and 84050).
https://burnstrauma.biomedcentral.com/track/p...017-0103-y
(5)
(0)